Welcome to our dedicated page for Aquestive Therapeutics SEC filings (Ticker: AQST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aquestive Therapeutics, Inc. filings document the regulatory, financial, governance, and capital-structure disclosures of a specialty pharmaceutical company built around oral-film drug delivery, proprietary product candidates, and CDMO/licensee manufacturing. Its 8-K reports include FDA communications and Regulation FD materials for Anaphylm™, financial results, investor presentations, and material agreements related to revenue-sharing, warrants, and common-stock purchase commitments.
Proxy materials describe annual-meeting voting matters, director elections, executive compensation, auditor ratification, and board governance. Other current reports record officer-transition matters, compensatory arrangements, exhibits, and product-development updates tied to the company’s regulatory strategy.
Aquestive Therapeutics director Timothy E. Morris received a grant of 50,500 stock options. These options give him the right to buy 50,500 shares of common stock at an exercise price of $3.99 per share. The options expire on June 10, 2036.
All of the underlying shares vest on June 10, 2027, provided Mr. Morris remains in continuous service with the company through that date. This is a compensation-related award rather than an open-market stock purchase or sale.
Aquestive Therapeutics director Julie Krop received a compensation-related stock option grant. She was awarded options to purchase 50,500 shares of Common Stock at an exercise price of $3.99 per share, expiring on June 10, 2036.
All 50,500 underlying shares vest 100% on June 10, 2027, subject to Dr. Krop’s continuous service with Aquestive Therapeutics through that date. After this grant, she holds 50,500 stock options directly, and the filing reports no share sales or open-market purchases.
Aquestive Therapeutics director Abigail L. Jenkins received an equity award of non-qualified stock options for 50,500 shares of common stock. The options have an exercise price of $3.99 per share, expire on June 10, 2036, and represent her direct holdings of this option grant.
All 50,500 underlying shares vest on June 10, 2027, provided she remains in continuous service with the company through that date. This is a compensation-related grant, not an open-market purchase or sale, so it mainly updates her potential future ownership rather than reflecting a trading decision.
Aquestive Therapeutics director John Cochran received a grant of 50,500 stock options on Common Stock as compensation. These options have an exercise price of $3.99 per share and expire on June 10, 2036. All 50,500 underlying shares vest on June 10, 2027, if he continues serving the company through that date.
Following this filing, Cochran directly holds 99,486 shares of Common Stock, separate from the new option award. The grant increases his potential future equity exposure but involves no open-market buying or selling of shares at this time.
Aquestive Therapeutics director Gregory B. Brown reported an equity compensation award. He received a grant of stock options covering 50,500 shares of Common Stock at an exercise price of $3.99 per share.
The options vest 100% on June 10, 2027, subject to his continuous service with the company through that date. Following this report, he directly holds 75,085 shares of Common Stock and the newly granted 50,500 stock options.
Aquestive Therapeutics director Marco Taglietti received a grant of stock options covering 50,500 shares of common stock. These options have an exercise price of $3.99 per share and expire on June 10, 2036. All 50,500 underlying shares vest on June 10, 2027, if he remains in continuous service through that date.
Aquestive Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 10, 2026. Stockholders elected three Class II directors — Gregory B. Brown, M.D., John S. Cochran, and Abigail L. Jenkins — to serve three-year terms until the 2029 annual meeting.
Stockholders also approved, on a non-binding advisory basis, the Company’s executive compensation program, with 37,798,609 votes for, 3,192,381 against, and 1,604,754 abstentions, plus 37,465,582 broker non-votes. In addition, they ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 78,804,323 votes for, 910,690 against, and 346,313 abstentions.
Aquestive Therapeutics, Inc. reported a routine insider tax event involving its Chief Commercial Officer, Sherry Korczynski. On this Form 4, the company withheld 2,714 shares of common stock to cover her tax withholding obligation tied to the vesting of previously granted RSUs.
These shares were not sold on the open market; they were retained by the issuer to satisfy taxes. After this withholding, Korczynski directly holds 238,403 shares of Aquestive Therapeutics common stock, reflecting her ongoing equity stake following the RSU vesting.
Aquestive Therapeutics reported that Chief Legal Officer Thomas A. Zalewski received equity-based compensation. He was granted 100,000 shares of restricted Common Stock, which will vest in three annual installments of 25%, 25%, and 50%. He also received a Non-Qualified Stock Option for 75,000 shares of Common Stock at an exercise price of $4.135 per share, vesting on the same 25%/25%/50% schedule and expiring in 2036. After these awards, his reported holdings from this grant are 100,000 shares of Common Stock and options for 75,000 underlying shares.
Aquestive Therapeutics President and CEO Daniel Barber reported an open-market sale of 8,257 shares of Common Stock. The weighted average sale price was $4.2889 per share, with individual trades ranging from $4.17 to $4.64. After this transaction, he directly holds 660,574 shares.